Invasive Fungal Infection
Top Cited Papers
- 19 April 2019
- journal article
- review article
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 116 (16), 271-+
- https://doi.org/10.3238/arztebl.2019.0271
Abstract
Background: The incidence of invasive fungal infection is approximately 6 cases per 100 000 persons per year. It is estimated that only half of such infections are detected during the patient's lifetime, making this one of the more common overlooked causes of death in intensive-care patients. The low detection rate is due in part to the complexity of the diagnostic work-up, in which the clinical, radiological, and microbiological findings must be considered. Fungi with resistance to antimycotic drugs have been found to be on the rise around the world. Methods: This review is based on pertinent publications retrieved from a selective search in PubMed, with special attention to guidelines on the diagnosis and treatment of invasive fungal infections caused by Candida spp., Aspergillus spp., Mucorales, and Fusarium spp. Resufts: The clinical risk factors for invasive fungal infection include, among others, congenital immune deficiency, protracted (>10 days) marked granulocytopenia (<0.5 x 10(9)/L), allogeneic stem-cell transplantation, and treatment with immunosuppressive drugs or corticosteroids. High-risk groups include patients in intensive care and those with structural pulmonary disease and/or complicated influenza. The first line of treatment, supported by the findings of random ed clinical trials. consists of echinocandins for infections with Candida spp. (candidemia response rates: 75.6% for anidulafungin vs. 60.2% for fluconazole) and azole antimycotic drugs for infections with Aspergillus spp. (response rates: 52.8% for voriconazole vs. 31.6% for conventional amphotericin B). The recommended first-line treatment also depends on the local epidemiology. This challenge should be met by interdisciplinary collaboration. Therapeutic decision-making should also take account of the often severe undesired effects of antimycotic drugs (including impairment of hepatic and/or renal function) and the numerous interactions that some of them have with other drugs. Conclusion: Invasive fungal infections are often overlooked in routine hospital care. They should be incorporated into antimicrobial stewardship programs as an essential component. There is also a pressing need for the development of new classes of antimycotic drug.Keywords
This publication has 81 references indexed in Scilit:
- Emerging fungal threats to animal, plant and ecosystem healthNature, 2012
- Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for ChemotherapyMycoses, 2011
- Risk assessment and prognostic factors for mould-related diseases in immunocompromised patientsJournal of Antimicrobial Chemotherapy, 2010
- Epidemic disease decimates amphibian abundance, species diversity, and evolutionary history in the highlands of central PanamaProceedings of the National Academy of Sciences, 2010
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Anidulafungin versus Fluconazole for Invasive CandidiasisNew England Journal of Medicine, 2007
- In vivo confocal microscopy in fungal keratitisBritish Journal of Ophthalmology, 2006
- Improved outcome in central nervous system aspergillosis, using voriconazole treatmentBlood, 2005
- Intracavitary administration of amphotericin B in the treatment of cerebral aspergillosis in a non immune-compromised patient: case report and review of the literatureBritish Journal Of Neurosurgery, 2000
- Candida Colonization and Subsequent Infections in Critically III Surgical PatientsAnnals of Surgery, 1994